No Data
Huachuang Securities: In the first quarter, the issuance of vaccine batches increased significantly, and the price of macrocyclic lactone veterinary medicine Active Pharmaceutical Ingredients continues to rise.
The demand for animal health products is gradually recovering, and by 2025, the breeding sector is expected to maintain profitability. The continuity of demand for animal health products may be ensured, and the Operation in the animal health Sector is gradually establishing a turning point.
WuHan Hvsen Biotechnology (300871.SZ): Currently, the capacity utilization rate of the company's raw material production lines for tartrate tilmicosin and tartrate tylosin is at a high level.
On April 17, Gelonghui reported that WuHan Hvsen Biotechnology (300871.SZ) stated on an interactive platform that the current capacity utilization rate of the company’s raw material production lines for Tylosin Tartrate and Tylvalosin Tartrate is at a high level. To better meet market demand, the company plans to upgrade the technology of its raw material production lines. After the completion of the upgrade project, the production capacity for Tylosin Tartrate Active Pharmaceutical Ingredient is expected to be 3,000 tons, with the project planned to begin production in the second quarter of this year.
WuHan Hvsen Biotechnology (300871.SZ): Produces and sells products related to gold mycin, accounting for a small proportion of revenue.
On April 7, Gelonghui reported that WuHan Hvsen Biotechnology (300871.SZ) stated on the investor interaction platform that the company does not have the production capacity for Active Pharmaceutical Ingredient related to chlortetracycline, and the production and sales of chlortetracycline-related dosage forms account for a small proportion of income.
WuHan Hvsen Biotechnology (300871.SZ): The company has no production capacity for the Active Pharmaceutical Ingredient of chlortetracycline.
On April 7, Gelonghui reported that WuHan Hvsen Biotechnology (300871.SZ) stated on the investor interaction platform that the company does not have the production capacity for Active Pharmaceutical Ingredient related to chlortetracycline, and the production and sales of chlortetracycline-related dosage forms account for a small proportion of income.
The price of veterinary drugs skyrocketed by 13.8%, WuHan Hvsen Biotechnology staged a "comeback", but how long can it last?
Speculative funds are frantically buying 0.12 billion.
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stock Catapults 30% Though Its Price And Business Still Lag The Industry
Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) 30% Jump Shows Its Popularity With Investors
